Company Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
2.250 ^USD	+7.14%		+14.21%	+44.23%

10-16	Alector Prices $75 Million Stock Offering	MT
10-16	Alector Prices $75 Million Stock Offering	MT

Business description: Alector, Inc.

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Number of employees: 103

Sales by Activity: Alector, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology	207M	134M	97.06M	101M	21.04M

See all business segments

Geographical breakdown of sales: Alector, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	207M	134M	97.06M	101M	21.04M

See all geographic segments

Executive Committee: Alector, Inc.

Manager	Title	Age	Since
Arnon Rosenthal CEO	Chief Executive Officer	71	2013-04-30
Neil Berkley DFI	Director of Finance/CFO	52	2025-06-19
Hua Long CTO	Chief Tech/Sci/R&D Officer	-	2016-12-31
Danielle Pasqualone LAW	General Counsel	-	-
Clare Hunt HRO	Human Resources Officer	-	2016-12-31

See ALECTOR, INC. governance

Composition of the Board of Directors: Alector, Inc.

Director	Title	Age	Since
Arnon Rosenthal BRD	Director/Board Member	71	2013-04-30
Richard Scheller BRD	Director/Board Member	72	2018-09-30
Louis Lavigne CHM	Chairman	77	2023-06-12
Kristine Yaffe BRD	Director/Board Member	63	2019-08-08
Paula Hammond BRD	Director/Board Member	62	2020-03-19
Elizabeth Garofalo BRD	Director/Board Member	68	2021-09-27
Errol de Souza BRD	Director/Board Member	72	2024-03-18
Mark Altmeyer BRD	Director/Board Member	65	2024-03-18

Composition of the Board of Directors

Shareholders: Alector, Inc.

Name	Stocks	%	Valuation
Deep Track Capital LP 8.615 %	12,772,152	8.615 %	24 M $
TCG Crossover Management LLC 6.745 %	10,000,000	6.745 %	19 M $
TCG Crossover Management LLC 6.745 %	10,000,000	6.745 %	19 M $
BVF Partners LP 6.323 %	9,374,267	6.323 %	17 M $
BlackRock Advisors LLC 5.091 %	7,547,967	5.091 %	14 M $

List of ALECTOR, INC. shareholders

Company details: Alector, Inc.

Alector, Inc.

131 Oyster Point Boulevard

94080-2029, South San Francisco

+415 231 5660

http://www.alector.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALECTOR, INC.	+7.14%	+14.21%	+50.00%	-56.14%	311M
WUXI APPTEC CO., LTD.	+0.65%	-3.56%	+33.53%	+60.50%	63.48B
ARGENX SE	+1.76%	+2.10%	+12.10%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.77%	+8.85%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-2.90%	+18.37%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-3.98%	+225.44%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.85%	+11.71%	+45.57%	32.47B
GENMAB A/S	+29.06%	+48.65%	+106.84%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-7.45%	+24.25%	-2.99%	23.36B
Average	+4.81%	+0.28%	+51.90%	+140.93%	38.07B
Weighted average by Cap.	+3.24%	-0.28%	+47.51%	+161.29%